Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Biosynex stock

ALBIO.PA
FR0011005933
A1H8G1

Price

2.05
Today +/-
-0.52
Today %
-22.56 %

Biosynex stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Biosynex stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Biosynex stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Biosynex stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Biosynex's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Biosynex Stock Price History

DateBiosynex Price
12/3/20242.05 undefined
12/2/20242.57 undefined
11/29/20242.62 undefined
11/28/20242.60 undefined
11/27/20242.68 undefined
11/26/20242.76 undefined
11/25/20242.78 undefined
11/22/20242.77 undefined
11/21/20242.88 undefined
11/20/20242.82 undefined
11/19/20242.87 undefined
11/18/20242.85 undefined
11/15/20242.73 undefined
11/14/20242.71 undefined
11/13/20242.82 undefined
11/12/20242.88 undefined
11/11/20242.93 undefined
11/8/20242.76 undefined
11/7/20242.92 undefined
11/6/20242.90 undefined
11/5/20242.90 undefined
11/4/20243.00 undefined

Biosynex Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Biosynex, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Biosynex from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Biosynex’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Biosynex. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Biosynex’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Biosynex’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Biosynex’s growth potential.

Biosynex Revenue, EBIT and net profit per share

DateBiosynex RevenueBiosynex EBITBiosynex Net Income
2025e146.47 M undefined5.97 M undefined5.1 M undefined
2024e127.31 M undefined618,000 undefined886,698.1 undefined
202392.98 M undefined-37.4 M undefined-37.12 M undefined
2022196.6 M undefined38.8 M undefined15.6 M undefined
2021382.5 M undefined140.6 M undefined104 M undefined
2020153.9 M undefined45.4 M undefined31.4 M undefined
201934.2 M undefined1.2 M undefined1.1 M undefined
201831.2 M undefined0 undefined500,000 undefined
201730.5 M undefined800,000 undefined300,000 undefined
201627 M undefined700,000 undefined-100,000 undefined
20159.9 M undefined-700,000 undefined-400,000 undefined
20144.1 M undefined-700,000 undefined-1.5 M undefined
20131.8 M undefined-1.1 M undefined-1.8 M undefined
20121.5 M undefined-800,000 undefined-700,000 undefined
20111.1 M undefined-400,000 undefined-300,000 undefined
20101 M undefined-100,000 undefined0 undefined
2009700,000 undefined-200,000 undefined-200,000 undefined
2008500,000 undefined-200,000 undefined-200,000 undefined
2007200,000 undefined-300,000 undefined-300,000 undefined
2006100,000 undefined-200,000 undefined-100,000 undefined

Biosynex Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
2006200720082009201020112012201320142015201620172018201920202021202220232024e2025e
00001111492730313415338219692127146
--------300.00125.00200.0011.113.339.68350.00149.67-48.69-53.0638.0414.96
----4,900.004,900.00100.00100.0050.0055.5651.8550.0051.6155.8845.1053.9352.0453.2638.5833.56
000000112514151619692061024900
0000000-1-1000013110415-3705
--------------3,000.00235.48-85.58-346.67--
--------------------
--------------------
0.20.20.40.50.61.21.31.41.76.48.19.19.19.19.211.110.310.4400
--------------------
Details

Keystats

ⓘ

Revenue and Growth

The Biosynex Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Biosynex is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200620072008200920102011201220132014201520162017201820192020202120222023
                                   
00000.14.53.321.11.10.6222.536.813287.226.16
000.10.10.30.30.51.10.82.45.43.42.92.811.525.314.710.65
0.10.10.10.10.10.10.30.30.40.611.20.91.95.89.418.910.67
0.10.10.20.20.20.20.40.51.31.666.56.27.832.531.237.738.21
0000000000.10.30.60.41.10.90.91.25.67
0.20.20.40.40.75.14.53.93.65.813.313.712.416.187.5198.8159.791.35
0.10.10.10.10.10.10.30.50.40.50.60.60.612.45.38.716.1
0000003.42.51.610.80.81.11.80012.85.12.93
0000000020010000000000
0.10.10.10.10.30.30.30.20.21.41.51.61.61.61.95.925.939.8
000000000.6922.923.122.827.629.346.260.991.54
000000.50.30.20.20.30.30.40.30.75000
0.20.20.20.20.40.94.33.43.222.126.126.827.130.938.670.2100.6150.38
0.40.40.60.61.168.87.36.827.939.440.539.547126.1269260.3241.73
                                   
0.10.20.30.500.10.10.10.20.60.80.90.90.90.91.111.08
00000.15.46.16.67.525.128.232.327.727.727.947.325.625.6
-0.1-0.4-0.6-0.80-0.4-1-2.8-4.3-4.6-4.7-4.30.51.937.5119.4135.997.81
00000000000010000000
000000000000000000
0-0.2-0.3-0.30.15.15.23.93.421.124.328.929.230.566.3167.8162.5124.48
00.10.10.30.30.30.40.30.81.94.632.83.719.618.71515.07
0000.10000.10.10.41.11.21.11.920.4289.49.69
00000.10.10.60.40.80.20.911.10.83.114.48.620.46
0.10.30.20.10.10.10.20.50.11.22.70.60.200.10.200.24
0.30000.30.10.40.40.4001.21.20666.75.94
0.40.40.30.50.80.61.61.72.23.79.376.46.449.267.339.751.4
00.10.40.300.221.61.23.25.74.63.89.79.829.245.359.58
000000000000000000
00.10.10.10.10.20.10000.10.100.414.78.46.44
00.20.50.40.10.42.11.61.23.25.84.73.810.110.833.953.766.02
0.40.60.80.90.913.73.33.46.915.111.710.216.560101.293.4117.41
0.40.40.50.616.18.97.26.82839.440.639.447126.3269255.9241.89
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Biosynex provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Biosynex's financial health and stability.

Assets

Biosynex's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Biosynex must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Biosynex after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Biosynex's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200720082009202020212022
0003110615
0007226
000000
000-70-37
000000
000000
000000
000311094
000-9-19-30
000-7-29-39
0001,000-9,000-9,000
000000
00061612
00040-1
0001014-10
-----1.00-21.00
000000
0003495-45
-0.2-0.3-0.122.590.8-25.2
000000

Biosynex stock margins

The Biosynex margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biosynex. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biosynex.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Biosynex's sales revenue. A higher gross margin percentage indicates that the Biosynex retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Biosynex's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Biosynex's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Biosynex's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Biosynex. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Biosynex's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Biosynex Margin History

Biosynex Gross marginBiosynex Profit marginBiosynex EBIT marginBiosynex Profit margin
2025e52.84 %4.08 %3.48 %
2024e52.84 %0.49 %0.7 %
202352.84 %-40.23 %-39.93 %
202252.03 %19.74 %7.93 %
202153.96 %36.76 %27.19 %
202045.03 %29.5 %20.4 %
201957.02 %3.51 %3.22 %
201851.92 %0 %1.6 %
201750.16 %2.62 %0.98 %
201652.59 %2.59 %-0.37 %
201556.57 %-7.07 %-4.04 %
201456.1 %-17.07 %-36.59 %
201377.78 %-61.11 %-100 %
201273.33 %-53.33 %-46.67 %
201181.82 %-36.36 %-27.27 %
201080 %-10 %0 %
200971.43 %-28.57 %-28.57 %
200880 %-40 %-40 %
2007100 %-150 %-150 %
2006100 %-200 %-100 %

Biosynex Stock Sales Revenue, EBIT, Earnings per Share

The Biosynex earnings per share therefore indicates how much revenue Biosynex has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Biosynex earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Biosynex's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Biosynex’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biosynex's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Biosynex Revenue, EBIT and net profit per share

DateBiosynex Sales per ShareBiosynex EBIT per shareBiosynex Earnings per Share
2025e13.61 undefined0 undefined0.47 undefined
2024e11.83 undefined0 undefined0.08 undefined
20238.9 undefined-3.58 undefined-3.55 undefined
202219.09 undefined3.77 undefined1.51 undefined
202134.46 undefined12.67 undefined9.37 undefined
202016.73 undefined4.93 undefined3.41 undefined
20193.76 undefined0.13 undefined0.12 undefined
20183.43 undefined0 undefined0.05 undefined
20173.35 undefined0.09 undefined0.03 undefined
20163.33 undefined0.09 undefined-0.01 undefined
20151.55 undefined-0.11 undefined-0.06 undefined
20142.41 undefined-0.41 undefined-0.88 undefined
20131.29 undefined-0.79 undefined-1.29 undefined
20121.15 undefined-0.62 undefined-0.54 undefined
20110.92 undefined-0.33 undefined-0.25 undefined
20101.67 undefined-0.17 undefined0 undefined
20091.4 undefined-0.4 undefined-0.4 undefined
20081.25 undefined-0.5 undefined-0.5 undefined
20071 undefined-1.5 undefined-1.5 undefined
20060.5 undefined-1 undefined-0.5 undefined

Biosynex business model

The company Biosynex SA was founded in 2005 in Strasbourg, France. The company is a manufacturer and distributor of diagnostic test kits used for the rapid and accurate diagnosis of various infectious diseases and other health conditions. Biosynex SA has established itself as a leading player in the global health market in recent years. The business model of Biosynex SA includes the design, manufacture, and distribution of various medical diagnostic tests that are capable of quickly and efficiently detecting pathogens and other health conditions. The company offers a wide range of medical test kits that can be used for the diagnosis of HIV/AIDS, hepatitis C, syphilis, rapid pregnancy tests, menopause, bleeding during pregnancy, vitamin D deficiency, and many other health conditions. The main focus of Biosynex SA is on developing test kits that are easy to use and provide accurate and reliable results. With its technological know-how and collaboration with leading experts in the field of medical diagnostics, Biosynex SA has taken a leading position in the development and marketing of medical diagnostic test kits. By collaborating with doctors, hospitals, and clinics globally, Biosynex SA has successfully expanded its business. Biosynex SA has various business areas specifically focused on the marketing and distribution of medical diagnostic tests. The most well-known areas include gynecology, infectious diseases, and pediatrics. Biosynex SA also has a strong presence in the global market, including Asia, Europe, Africa, and America. One of the most well-known products of Biosynex SA is the HIV self-test called Autotest VIH®, which is available in many European countries and North America. The test kit is CE marked and approved by leading health authorities such as the WHO and the EU. The product is an important tool in reducing the spread of HIV infections and allowing people to make a confidential diagnosis of HIV/AIDS in a private setting. In the field of gynecology, Biosynex SA offers various products such as the Unistick® pregnancy test, Unistick® ovulation test, and Unistick® menopause test kit. These products enable women to easily and efficiently diagnose pregnancy, ovulation, and menopause. The test kits are easy to use, can be used at home, and provide results within minutes. In summary, Biosynex SA has earned its leading position in the global market due to its focus on innovative technology and high-quality product range. The company has made a significant contribution to improving healthcare worldwide with its expertise and commitment to diagnosing health conditions. Biosynex SA will continue to expand its business in the future to support even more people worldwide and further improve the quality of healthcare. Biosynex is one of the most popular companies on Eulerpool.com.

Biosynex SWOT Analysis

Strengths

1. Established Reputation: Biosynex SA has built a strong reputation in the market for its reliable and high-quality medical diagnostics products.

2. Innovative Product Range: The company offers a diverse range of innovative diagnostic tests and kits, catering to various medical needs.

3. Strong Distribution Network: Biosynex has a wide distribution network, enabling it to reach healthcare professionals and consumers efficiently.

Weaknesses

1. Dependence on External Suppliers: Biosynex relies on external suppliers for certain components, posing a risk for supply chain disruptions.

2. Limited Global Presence: The company's market presence is primarily focused on Europe, limiting its exposure to potential growth opportunities in other regions.

3. Relatively Small Scale: Compared to larger competitors, Biosynex operates on a smaller scale, which may limit its ability to compete in terms of economies of scale.

Opportunities

1. Growing Demand for Diagnostic Tests: The increasing global focus on healthcare and disease prevention presents an opportunity for Biosynex to expand its customer base.

2. Emerging Markets: The company can explore and expand into emerging markets, leveraging its expertise and product portfolio.

3. Strategic Partnerships: Collaborating with other healthcare companies or research institutions can help Biosynex develop innovative solutions and expand its market reach.

Threats

1. Intense Competition: The medical diagnostics industry is highly competitive, with both established players and new entrants vying for market share.

2. Regulatory Challenges: Adhering to evolving regulatory standards and obtaining necessary approvals for products can pose challenges and impact time-to-market.

3. Economic Factors: Economic fluctuations, pricing pressures, and healthcare budget constraints can affect demand for Biosynex's products.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Biosynex Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Biosynex historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Biosynex shares outstanding

The number of shares was Biosynex in 2023 — This indicates how many shares 10.444 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Biosynex earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Biosynex's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Biosynex’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biosynex's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Biosynex dividend history and estimates

In 2023, Biosynex paid a dividend amounting to 0 EUR. Dividend means that Biosynex distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Biosynex provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Biosynex’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Biosynex's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Biosynex Dividend History

DateBiosynex Dividend
2025e0.42 undefined
2024e0.06 undefined
20222 undefined
20210.2 undefined

Biosynex dividend payout ratio

In 2023, Biosynex had a payout ratio of 66.86%. The payout ratio indicates the percentage of the company's profits that Biosynex distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Biosynex represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Biosynex could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Biosynex's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Biosynex Payout Ratio History

DateBiosynex Payout ratio
2025e88.43 %
2024e66.86 %
202366.86 %
2022131.58 %
20212.14 %
202066.86 %
201966.86 %
201866.86 %
201766.86 %
201666.86 %
201566.86 %
201466.86 %
201366.86 %
201266.86 %
201166.86 %
201066.86 %
200966.86 %
200866.86 %
200766.86 %
200666.86 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Biosynex.

Biosynex shareholders

%
Name
Stocks
Change
Date
34.94127 % ALA Financi¿re3,759,995012/31/2023
9.24454 % AJT Financi¿re994,796012/31/2023
6.20048 % Abensur (Larry)667,227012/31/2023
2.62945 % Axodev282,952012/31/2023
1.56292 % Lamy (Thomas)168,184012/31/2023
0.99468 % Paper (Thierry)107,036012/31/2023
0.69697 % Sunny Asset Management75,00008/31/2024
0.38106 % Mandarine Gestion41,0063,5069/30/2023
0.12673 % Avantis Investors13,63703/31/2024
0.03785 % American Century Investment Management, Inc.4,073-10,2066/30/2024
1
2

Most common questions regarding Biosynex

What values and corporate philosophy does Biosynex represent?

Biosynex SA represents strong values and a clear corporate philosophy. The company's main focus is on providing innovative and reliable diagnostic solutions to improve patient care. Biosynex SA's values include integrity, excellence, and collaboration, aiming to deliver high-quality and accurate diagnostic tests. The company is committed to sustainability, ensuring that its operations are environmentally responsible. With a customer-centric approach, Biosynex SA strives to meet the evolving needs of healthcare professionals and patients. Through continuous innovation and a strong commitment to quality, Biosynex SA aims to make a positive impact in the field of medical diagnostics.

In which countries and regions is Biosynex primarily present?

Biosynex SA is primarily present in various countries and regions worldwide. The company operates in several European countries, including France, Germany, Italy, Spain, and the United Kingdom. In addition, Biosynex SA has a presence in other regions such as North America, Africa, and Asia. With its diverse portfolio of innovative medical diagnostic solutions, Biosynex SA has expanded its market reach to serve healthcare professionals and patients globally.

What significant milestones has the company Biosynex achieved?

Biosynex SA has achieved several significant milestones throughout its journey. The company has made substantial advancements in the field of diagnostic testing by developing innovative and reliable solutions. Biosynex SA has successfully initiated strategic partnerships and collaborations, expanding its global presence. Moreover, the company has gained regulatory approvals and certifications, ensuring the quality and safety of its products. With a commitment to continuous research and development, Biosynex SA has consistently introduced cutting-edge technologies to enhance healthcare outcomes. These milestones reflect Biosynex SA's dedication to providing breakthrough diagnostic solutions, positioning the company as a leader in the industry.

What is the history and background of the company Biosynex?

Biosynex SA is a prominent company specializing in the field of medical diagnostics. Established in 2005, Biosynex has emerged as a leading player in the global healthcare industry. The company focuses on developing and manufacturing innovative diagnostic solutions, including rapid tests, for a wide range of medical conditions. With a strong commitment to research and development, Biosynex has achieved significant milestones in the diagnosis of various diseases, such as infectious diseases, women’s health, and cardiovascular disorders. Through strategic collaborations and a customer-centered approach, Biosynex SA continues to revolutionize the medical diagnostics landscape, ensuring accurate and efficient testing for patients worldwide.

Who are the main competitors of Biosynex in the market?

The main competitors of Biosynex SA in the market include (insert competitors' names). The company operates in a highly competitive industry, and these competitors pose a challenge in terms of market share and product offerings. Biosynex SA has been consistently striving to differentiate itself through innovative products, strong marketing strategies, and extensive market presence. Despite the competitive landscape, Biosynex SA has successfully maintained its position and continues to expand its customer base through its commitment to quality, customer satisfaction, and continuous improvement.

In which industries is Biosynex primarily active?

Biosynex SA is primarily active in the healthcare industry.

What is the business model of Biosynex?

The business model of Biosynex SA revolves around the development, manufacturing, and distribution of rapid diagnostic tests (RDTs) for various medical conditions. Biosynex SA focuses on providing innovative and user-friendly diagnostic solutions that offer fast and reliable results. By leveraging cutting-edge technology and scientific expertise, Biosynex SA aims to improve the accessibility and efficiency of medical testing procedures. Their wide range of rapid diagnostic tests covers areas such as infectious diseases, women's health, gastroenterology, and cardiovascular conditions. Biosynex SA strives to contribute to better healthcare outcomes by offering accurate and time-sensitive diagnostic tools to healthcare professionals and patients alike.

What is the P/E ratio of Biosynex 2024?

The Biosynex P/E ratio is 24.09.

What is the P/S ratio of Biosynex 2024?

The Biosynex P/S ratio is 0.17.

What is the Quality Investing of Biosynex?

The Quality Investing for Biosynex is 4/10.

What is the revenue of Biosynex 2024?

The expected Biosynex revenue is 127.31 M EUR.

How high is the profit of Biosynex 2024?

The expected Biosynex profit is 886,698.1 EUR.

What is the business model of Biosynex

Biosynex SA is a French company based in Strasbourg that specializes in the development, production, and marketing of rapid tests and other diagnostic solutions. The company was founded in 2005 and has since built up a wide portfolio of products that can be used in various areas such as healthcare, pregnancy, sexually transmitted diseases, and more. The business model of Biosynex SA is based on the manufacture and sale of rapid and easy diagnostic tests that can be used by medical professionals and end consumers. The company offers a wide range of diagnostic solutions, from pregnancy tests to tests for infectious diseases such as HIV, hepatitis B and C, as well as tests for cardiovascular diseases and drug abuse. An important sector of Biosynex SA is the healthcare sector. Here, the company offers various tests that can help detect diseases early and provide a quick diagnosis. These include tests for cholesterol, blood sugar, blood pressure, and other indicators of cardiovascular diseases. In addition, Biosynex SA also offers tests for body fluids such as urine and stool, which can help detect diseases such as urinary tract infections or colorectal cancer early. Another important area of Biosynex SA is the pregnancy sector. Here, the company offers fast and reliable tests that can usually be performed at home. Products in this category include pregnancy tests and ovulation tests, which can help women identify their fertile days and plan for pregnancy. Another important area of Biosynex SA is the sexually transmitted diseases sector. Here, the company offers tests for a variety of infectious diseases, including HIV, hepatitis B and C, chlamydia, and gonorrhea. These tests are easy to perform and can help detect and treat infections early. In addition to these important product categories, Biosynex SA also offers a range of diagnostic solutions that can be used in various medical fields. These include tests for drug abuse, respiratory diseases, anemia, and more. The business model of Biosynex SA is based on the production and sale of fast and reliable diagnostic tests that can be used in various medical fields. The company aims to expand its product range through continuous research and development and to create innovations that can help improve patients' lives and enhance the quality of medical care. The answer is: Biosynex SA is a French company specializing in the development and production of rapid tests and diagnostic solutions for various areas such as healthcare, pregnancy, sexually transmitted diseases, and more. They offer a wide range of tests for different medical needs and aim to improve patients' lives through research and development.

What is the Biosynex dividend?

Biosynex pays a dividend of 2 EUR distributed over payouts per year.

How often does Biosynex pay dividends?

The dividend cannot currently be calculated for Biosynex or the company does not pay out a dividend.

What is the Biosynex ISIN?

The ISIN of Biosynex is FR0011005933.

What is the Biosynex WKN?

The WKN of Biosynex is A1H8G1.

What is the Biosynex ticker?

The ticker of Biosynex is ALBIO.PA.

How much dividend does Biosynex pay?

Over the past 12 months, Biosynex paid a dividend of 2 EUR . This corresponds to a dividend yield of about 97.8 %. For the coming 12 months, Biosynex is expected to pay a dividend of 0.42 EUR.

What is the dividend yield of Biosynex?

The current dividend yield of Biosynex is 97.8 %.

When does Biosynex pay dividends?

Biosynex pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Biosynex?

Biosynex paid dividends every year for the past 2 years.

What is the dividend of Biosynex?

For the upcoming 12 months, dividends amounting to 0.42 EUR are expected. This corresponds to a dividend yield of 16.33 %.

In which sector is Biosynex located?

Biosynex is assigned to the 'Health' sector.

Wann musste ich die Aktien von Biosynex kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Biosynex from 5/18/2022 amounting to 2 EUR, you needed to have the stock in your portfolio before the ex-date on 5/16/2022.

When did Biosynex pay the last dividend?

The last dividend was paid out on 5/18/2022.

What was the dividend of Biosynex in the year 2023?

In the year 2023, Biosynex distributed 2 EUR as dividends.

In which currency does Biosynex pay out the dividend?

The dividends of Biosynex are distributed in EUR.

All fundamentals about Biosynex

Our stock analysis for Biosynex Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biosynex Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.